A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Status:
Completed
Trial end date:
2020-08-21
Target enrollment:
Participant gender:
Summary
This Phase 1, open-label, multicenter, global study will evaluate the safety,
pharmacokinetics, and activity of emactuzumab and atezolizumab administered in combination in
participants with selected locally advanced or metastatic solid tumors that are not amenable
to standard treatment.
Participants who receive emactuzumab and atezolizumab will continue to receive study drug as
long as they experience clinical benefit in the opinion of the investigator or until
unacceptable toxicity or symptomatic deterioration attributed to disease progression as
determined by the investigator after an integrated assessment of radiographic data, biopsy
results (if available), and clinical status, or withdrawal of consent.